SPARK by NCIS - Our Annual Publication

Click for more info on presentations received by our NCIS clinicians at the European Society for Medical Oncology (ESMO) Congress 2024:

• Pembrolizumab plus lenvatinib in recurrent clear cell gynecological cancer: Phase II LARA trial (GCGS-OV4/ APGOT-OV3)

Click for more info on awards and presentations received by our NCIS clinician at the World Conference on Lung Cancer 2024:

• IASLC Academy Award

Click for more info on awards and presentations received by our NCIS clinician at the American Society of Clinical Oncology (ASCO) Breakthrough Meeting 2024:

• A phase Ib/II study of pacritinib, an interleukin 1 receptor associated kinase 1 (IRAK1) inhibitor, in patients (pts) with solid tumors harboring the 1q21.3 copy number amplification (CNA)

​​​Click for more info on the presentations:

• Low prevalence of cardiovascular risk factors in persons aged fifty years or younger with venous thromboembolism
• Performance Of Chemiluminescence Assays for Laboratory Diagnosis of Antiphospholipid Syndrome – A Single Centre Experience

​​​Click for more info on the presentations:

• FLAG-IDA + venetoclax (ven) in newly diagnosed (ND) or relapsed/refractory (RR) AML
• Indirect treatment comparisons of daratumumab-pomalidomide-dexamethasone (DPD) and pomalidomide-bortezomib-dexamethasone (PVD) in relapsed/refractory multiple myeloma (RRMM)
• Role of autologous stem cell transplantation in patients with primary CNS lymphoma: real-world data from a retrospective multi-centre analysis

​​​​Click for more info on the poster presentations:

• Multi-ethnic genome-wide association study to identify a novel locus for susceptibility to immunerelated adverse events from immune checkpoint inhibitors
• FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML
• A phase 2 study of trifluridine/tipiracil (FTD/TPI) in recurrent/metastatic nasopharyngeal (r/m NPC) carcinomas with or without prior exposure to fluoropyrimidines

​​​​Click for more info on the poster presentations:

• CT160 – A phase I trial to evaluate allogenic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T cells in subjects with advanced solid tumors or haematological malignancies (the ANGELICA trial)

​​​​Click for more info on the poster presentations:

• Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center

​​​​Click for more info on the poster presentations:

• Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study
• HLA-Haploidentical Hematopoietic Cell Transplantation of Ex Vivo Tcrαβ-Depleted Grafts with CD45RA-Depleted Memory T Cell Add-Back in Adults and Children with Hematological Malignancies: 4-Year Follow-up of Multicenter Study in Singapore
• Cepp in Previously Untreated Patients with Mature T Cell Lymphomas
• Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies
• Single Cell Multi-Omic Profiling of Multiple Myeloma with t(4;14) Finds an Immune Microenvironment Gene Signature That Correlates with Clinical Outcomes
• Evaluating Front Line Treatment Regimens for Waldenstrom Macroglobulinaemia: A Systematic Review and Meta-Analysis
• Graft-Vs-Host Disease (GvHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCy) and Thymoglobulin (ATG) Are More Important Determinants of Cytomegalovirus (CMV) Reactivation after Allogeneic Hematopoietic Cell Transplantation (HCT) Than Ex-Vivo T-Cell Depletion in the Era of Pre-Emptive Therapy
• Lenalidomide Compared to Ixazomib Maintenance in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
• Safety, Feasibility and Healthcare Cost Differences between Inpatient and Outpatient Mobilization Chemotherapy for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Single Center Experience

​​​​​Click for more info on the research studies:

• Determinants of response to Daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma
• International consensus guidelines on liver transplantation for non-resectable colorectal liver metastases
• Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition

​​​​​​Click for more info on the poster presentations:

• 515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)
• 1699P Introduction of the GOLDEN (Geriatric Oncology LongituDinal End to eNd) programme in a tertiary cancer centre